Cytogenetics and Prognostic Models in Myelodysplastic Syndromes

Uma Borate, Harry P. Erba

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Myelodysplastic syndromes (MDS), discussed in this chapter, are a heterogeneous group of clonal hematopoietic disorders that have an increased risk of progression to acute myeloid leukemia (AML). The prognosis of MDS patients varies significantly based on both patient and disease characteristics. Various classifications have been proposed to better prognosticate patient outcomes. The French-American-British (FAB) classification is the oldest scheme for classifying MDS, dividing it into five subtypes. The World Health Organization (WHO) reclassified MDS in 2000 and 2008 based on clinical data, but the system remained predominantly a morphologic classification. Today, the most widely accepted MDS prognostic models are based predominantly on marrow morphology, cytogenetics, and cytopenias. However, prognostic models are only valid in the context of available therapies and thus have limited use, basically just identifying patients with high-risk disease who should proceed to allogeneic hematopoietic stem cell transplantation, if possible. Our knowledge of both somatic mutations and epigenetic abnormalities in this disease is increasing rapidly, and these findings are likely to be incorporated into future prognostic models and may help guide therapeutic options.

Original languageEnglish (US)
Title of host publicationCancer Consult: Expertise for Clinical Practice
PublisherWiley Blackwell
Pages106-112
Number of pages7
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
DOIs
StatePublished - Jun 20 2014
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Cytogenetics
Hematopoietic Stem Cell Transplantation
Information Systems
Acute Myeloid Leukemia
Epigenomics
Bone Marrow
Mutation
Therapeutics

Keywords

  • Clonal hematopoietic disorders
  • French-American-British (FAB) classification of MDS
  • MDS prognostic models
  • Myelodysplastic syndromes (MDS)
  • World Health Organization (WHO) classification of MDS

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Borate, U., & Erba, H. P. (2014). Cytogenetics and Prognostic Models in Myelodysplastic Syndromes. In Cancer Consult: Expertise for Clinical Practice (pp. 106-112). Wiley Blackwell. https://doi.org/10.1002/9781118589199.ch15

Cytogenetics and Prognostic Models in Myelodysplastic Syndromes. / Borate, Uma; Erba, Harry P.

Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell, 2014. p. 106-112.

Research output: Chapter in Book/Report/Conference proceedingChapter

Borate, U & Erba, HP 2014, Cytogenetics and Prognostic Models in Myelodysplastic Syndromes. in Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell, pp. 106-112. https://doi.org/10.1002/9781118589199.ch15
Borate U, Erba HP. Cytogenetics and Prognostic Models in Myelodysplastic Syndromes. In Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell. 2014. p. 106-112 https://doi.org/10.1002/9781118589199.ch15
Borate, Uma ; Erba, Harry P. / Cytogenetics and Prognostic Models in Myelodysplastic Syndromes. Cancer Consult: Expertise for Clinical Practice. Wiley Blackwell, 2014. pp. 106-112
@inbook{35457dc5388542069094c3c25a62a6ee,
title = "Cytogenetics and Prognostic Models in Myelodysplastic Syndromes",
abstract = "Myelodysplastic syndromes (MDS), discussed in this chapter, are a heterogeneous group of clonal hematopoietic disorders that have an increased risk of progression to acute myeloid leukemia (AML). The prognosis of MDS patients varies significantly based on both patient and disease characteristics. Various classifications have been proposed to better prognosticate patient outcomes. The French-American-British (FAB) classification is the oldest scheme for classifying MDS, dividing it into five subtypes. The World Health Organization (WHO) reclassified MDS in 2000 and 2008 based on clinical data, but the system remained predominantly a morphologic classification. Today, the most widely accepted MDS prognostic models are based predominantly on marrow morphology, cytogenetics, and cytopenias. However, prognostic models are only valid in the context of available therapies and thus have limited use, basically just identifying patients with high-risk disease who should proceed to allogeneic hematopoietic stem cell transplantation, if possible. Our knowledge of both somatic mutations and epigenetic abnormalities in this disease is increasing rapidly, and these findings are likely to be incorporated into future prognostic models and may help guide therapeutic options.",
keywords = "Clonal hematopoietic disorders, French-American-British (FAB) classification of MDS, MDS prognostic models, Myelodysplastic syndromes (MDS), World Health Organization (WHO) classification of MDS",
author = "Uma Borate and Erba, {Harry P.}",
year = "2014",
month = "6",
day = "20",
doi = "10.1002/9781118589199.ch15",
language = "English (US)",
isbn = "9781118589212",
pages = "106--112",
booktitle = "Cancer Consult: Expertise for Clinical Practice",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Cytogenetics and Prognostic Models in Myelodysplastic Syndromes

AU - Borate, Uma

AU - Erba, Harry P.

PY - 2014/6/20

Y1 - 2014/6/20

N2 - Myelodysplastic syndromes (MDS), discussed in this chapter, are a heterogeneous group of clonal hematopoietic disorders that have an increased risk of progression to acute myeloid leukemia (AML). The prognosis of MDS patients varies significantly based on both patient and disease characteristics. Various classifications have been proposed to better prognosticate patient outcomes. The French-American-British (FAB) classification is the oldest scheme for classifying MDS, dividing it into five subtypes. The World Health Organization (WHO) reclassified MDS in 2000 and 2008 based on clinical data, but the system remained predominantly a morphologic classification. Today, the most widely accepted MDS prognostic models are based predominantly on marrow morphology, cytogenetics, and cytopenias. However, prognostic models are only valid in the context of available therapies and thus have limited use, basically just identifying patients with high-risk disease who should proceed to allogeneic hematopoietic stem cell transplantation, if possible. Our knowledge of both somatic mutations and epigenetic abnormalities in this disease is increasing rapidly, and these findings are likely to be incorporated into future prognostic models and may help guide therapeutic options.

AB - Myelodysplastic syndromes (MDS), discussed in this chapter, are a heterogeneous group of clonal hematopoietic disorders that have an increased risk of progression to acute myeloid leukemia (AML). The prognosis of MDS patients varies significantly based on both patient and disease characteristics. Various classifications have been proposed to better prognosticate patient outcomes. The French-American-British (FAB) classification is the oldest scheme for classifying MDS, dividing it into five subtypes. The World Health Organization (WHO) reclassified MDS in 2000 and 2008 based on clinical data, but the system remained predominantly a morphologic classification. Today, the most widely accepted MDS prognostic models are based predominantly on marrow morphology, cytogenetics, and cytopenias. However, prognostic models are only valid in the context of available therapies and thus have limited use, basically just identifying patients with high-risk disease who should proceed to allogeneic hematopoietic stem cell transplantation, if possible. Our knowledge of both somatic mutations and epigenetic abnormalities in this disease is increasing rapidly, and these findings are likely to be incorporated into future prognostic models and may help guide therapeutic options.

KW - Clonal hematopoietic disorders

KW - French-American-British (FAB) classification of MDS

KW - MDS prognostic models

KW - Myelodysplastic syndromes (MDS)

KW - World Health Organization (WHO) classification of MDS

UR - http://www.scopus.com/inward/record.url?scp=84946411285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946411285&partnerID=8YFLogxK

U2 - 10.1002/9781118589199.ch15

DO - 10.1002/9781118589199.ch15

M3 - Chapter

AN - SCOPUS:84946411285

SN - 9781118589212

SP - 106

EP - 112

BT - Cancer Consult: Expertise for Clinical Practice

PB - Wiley Blackwell

ER -